We firstly determined if the microtissues recapitulated the molecular signatures of processes that occur early in the development of NAFLD in humans, namely lipid accumulation, insulin resistance, mitochondrial dysfunction and changes to the poly (ADP-ribose) polymerases (PARP) pathway. This evidence concerns the gene PARP1 and metabolic dysfunction-associated steatotic liver disease.